Ferrous bisglycinate, an innovative amino acid iron chelate, showed increased absorption and fewer gastrointestinal side effects when used as an iron supplement in pregnant women.
The team carried out a systematic review and meta-analysis of randomized controlled trials (RCTs) through a comprehensive survey of electronic databases and grey literature up to July 17, 2020, to ascertain the impacts of ferrous bisglycinate versus other iron supplements on hemoglobin and ferritin levels and gastrointestinal (GI) adverse events. Exercises were undertaken to calculate averages from these trials which involved pregnant women and children and these average estimates were communicated as standardized mean differences. The rate of occurrence for GI adverse events was determined using Poisson generalized linear mixed-effects models. Studies involving other subjects (men and non-pregnant women) were evaluated on an individual basis.
Discussion of Results: The results reveal fermentable bisglycinate demonstrating an advantage over other iron supplements. Among the pregnant women involved in the trials, those using this supplement had higher hemoglobin levels after 4-20 weeks of administration. Additionally, these women reported reduced GI adverse events. Although the observed increase in ferritin levels was not marked as significant, it depicted an upward trend. However, no notable differences were detected in either hemoglobin or ferritin concentrations in children using ferrous bisglycinate.
